Date: 2018-01-17
Type of information: Nomination
Compound: chief financial officer and chief business officer
Company: Orchard Therapeutics (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 17, 2018,Orchard Therapeutics announced the appointment of Frank Thomas to the newly created position of chief financial officer and chief business officer. Thomas brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive with an extensive set of capabilities to Orchard. Mr. Thomas has a background developing and executing capital markets strategies for private and public companies as well as experience in operations management, and corporate and business development. He joins Orchard Therapeutics to oversee the company’s global finance and business development teams.
- Until recently Thomas served as president and chief operating officer of AMAG Pharmaceuticals where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Mr. Thomas raised more than $1.8 billion in new capital to support the significant growth of AMAG. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, a commercial stage medical diagnostics company. Earlier in his career, Mr. Thomas also served as chief financial officer for Critical Therapeutics and Esperion Therapeutics. Each completed its IPO in the United States during his tenure.
- Mr. Thomas currently serves on the board of directors of Zafgen and Spero Therapeutics where he is also chairman of the audit committees. Mr. Thomas received a Bachelor of Business Administration (BBA) from the University of Michigan, Ann Arbor.
Financial terms:
Latest news:
Is general: Yes
